AGIOS PHARMACEUTICALS, INC. APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition
AGIOS PHARMACEUTICALS, INC. (AGIO) reported APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition of $6.00 thousand for the 12-month period ending 2015-12-31, per its 10-K filed 2018-02-14.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition · last filed 2018-02-14
- AGIOS PHARMACEUTICALS, INC. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for fiscal 2015 was $6.00K, a 33.33% decline from fiscal 2014.
- AGIOS PHARMACEUTICALS, INC. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for fiscal 2014 was $9.00K, a 85.94% decline from fiscal 2013.
- AGIOS PHARMACEUTICALS, INC. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for fiscal 2013 was $64.00K, a 14.29% increase from fiscal 2012.
- AGIOS PHARMACEUTICALS, INC. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for fiscal 2012 was $56.00K, a 0.00% change from fiscal 2011.
| Period end | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 12 month |
|---|---|
| 2015-12-31 | $6.00K 10-K · filed 2018-02-14 |
| 2014-12-31 | $9.00K 10-K · filed 2017-02-16 |
| 2013-12-31 | $64.00K 10-K · filed 2016-02-26 |
| 2012-12-31 | $56.00K 10-K · filed 2015-02-24 |
| 2011-12-31 | $56.00K 10-K · filed 2014-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |